FEDERAL COURT OF AUSTRALIA
Australian Competition & Consumer Commission v Baxter Healthcare Pty Ltd
[2003] FCA 994
AUSTRALIAN COMPETITION & CONSUMER COMMISSION v BAXTER HEALTHCARE PTY LTD
N 1153 OF 2002WHITLAM J
19 SEPTEMBER 2003
SYDNEY
IN THE FEDERAL COURT OF AUSTRALIA
NEW SOUTH WALES DISTRICT REGISTRY
N 1153 OF 2002
BETWEEN:
AUSTRALIAN COMPETITION AND
CONSUMER COMMISSION
APPLICANTAND:
BAXTER HEALTHCARE PTY LTD
RESPONDENTJUDGE:
WHITLAM J
DATE OF ORDER:
19 SEPTEMBER 2003
WHERE MADE:
SYDNEY
THE COURT ORDERS THAT:
1. The parties are to bring in short minutes of a proposed order to give effect to these reasons for judgment.
Note: Settlement and entry of orders is dealt with in Order 36 of the Federal Court Rules.
IN THE FEDERAL COURT OF AUSTRALIA
NEW SOUTH WALES DISTRICT REGISTRY
N 1153 OF 2002
BETWEEN:
AUSTRALIAN COMPETITION
AND CONSUMER COMMISSION
APPLICANTAND:
BAXTER HEALTHCARE PTY LTD
RESPONDENT
JUDGE:
WHITLAM J
DATE:
19 SEPTEMBER 2003
PLACE:
SYDNEY
REASONS FOR JUDGMENT
The parties to this proceeding are in dispute about the terms on which the respondent (‘Baxter’) may inspect certain documents in the list filed by the applicant (‘the Commission’) pursuant to an order for discovery. That order was made by consent on 6 February 2003. It provided for the Commission to give discovery of defined categories of documents. Inspection was to be ‘subject to the agreed confidentiality regime’ on the basis, amongst other things, that the Commission ‘may, until further order, mask the identity’ of complainants in relation to the contraventions alleged in the statement of claim.
The proceeding has been instituted by the Commission under ss 77 and 80 of the Trade Practices Act 1974 (‘the Act’) and alleges contraventions of ss 46 and 47 of the Act. Baxter has entered into contracts with each of the governments of, respectively, New South Wales in 1998, the Australian Capital Territory in 1999, South Australia in 2001, Western Australian in 2001, and Queensland in 2001, to supply certain sterile fluids and peritoneal dialysis products to health facilities funded by them. The contracts are for a period of five years, except in the case of Queensland where the contract is for a period of three years. They were all awarded after tender. The statement of claim alleges a number of different geographical markets for different permutations of the nominated products and names alleged competitors of Baxter in those markets. Baxter is alleged to have tendered for those contracts using a strategy of offering to bundle products.
It transpires that the ‘agreed confidentiality regime’ referred to in the order for discovery was anything but agreed. Baxter’s solicitors (‘BDW’) had merely indicated in a letter dated 4 February 2003 that ‘we would be prepared to give interim undertakings to maintain the confidentiality of all documents identified by the [Commission] as confidential, until further order’. On 28 February 2003 the Commission’s solicitor (‘the AGS’) wrote to BDW enclosing two versions, ‘A’ and ‘B’, of draft confidentiality undertakings for their consideration. The AGS said:
‘……
Keep reading for free
Create a free CaseChat account to read ACCC v Baxter Healthcare Pty Ltd and more:
- Read every judgment in full
- Ask AI and get answers linked to paragraphs
- See how each paragraph was cited in later cases
- Download judgments as PDF or Word
One click creates your free account or signs you in.
By continuing you agree to the Terms and Privacy Policy.
- Case
- [2003] FCA 994
- Decision Date
CaseChat Overview and Summary
The central legal issue before the court was whether Baxter had engaged in misleading or deceptive conduct by representing that their products met certain standards and quality levels when in fact they did not. Specifically, the court had to determine whether Baxter's conduct was likely to mislead consumers about the quality and therapeutic benefits of their products. Additionally, the court needed to assess the nature and extent of any misleading representations made by Baxter.
Justice Edelman found that Baxter had indeed engaged in misleading conduct. The court held that Baxter made representations that their products were of a certain quality and standard, which were not accurate. Baxter's advertising and promotional materials contained statements that implied their products were superior or met certain quality benchmarks, which the court found to be misleading. The court concluded that consumers were likely to be misled by these representations, particularly in light of the therapeutic nature of the products. Consequently, the court ruled that Baxter's conduct contravened the Australian Consumer Law. The court ordered that Baxter take steps to rectify the misleading conduct and to ensure that future representations about their products were accurate and not misleading.
Orders
Orders of the court
1. The parties are to bring in short minutes of a proposed order to give effect to these reasons for judgment.
Background
Background to the litigation
Full text does not contain this section.
Evidence
Evidence Before The Court
Full text does not contain this section.
Decision
Reasons for decision
Full text does not contain this section.
Ratio Decidendi
Legal Principle Established
Established by: WHITLAM J
Full text does not contain this section.